PHP51 Managements of Febrile Neutropenia among Non-Hodgkin's Lymphoma Patients in Taiwan

W. T. Lin,F. Y. Hsiao,S. C. Chiang,Y. W. Wen

DOI: https://doi.org/10.1016/j.jval.2012.08.102

IF: 5.156

2012-01-01

Value in Health

Abstract:Febrile neutropenia (FN) is a major complication in cancer patients treated with chemotherapy, leading to infection-associated morbidity and mortality. Therefore, prophylactic use of granulocyte colony-stimulating factor (G-CSF) is recommended by recent clinical guidelines to manage those patients with high risk of FN. Uncertainty in selecting patients who need G-CSF prophylaxis, however, remains in clinical settings. The objectives of this study were to document the utilization pattern of G-CSF and to analyze the potential risk factors of FN in non-Hodgkin's lymphoma (NHL) patients. Eligible patients were those who were older than 18 years, diagnosed with NHL, and initiated a new chemotherapy regimen in 2010 at a medical center in Taiwan. All chemotherapy cycles received by our study subjects were divided into two groups based on the occurrence of FN during each cycle. All patients were followed until all the planned chemotherapy courses were completed or one year after the first date of chemotherapy regimen. Differences in patient characteristics between the FN and non-FN group were assessed with chi-square tests for categorical variables and t-tests for continuous variables. Two hundred and eighty-six courses for G-CSF prophylaxis were evaluated in 72 patients receiving a total of 432 cycles of chemotherapy regimen. Of these, 38 % of G-CSF was prescribed as primary prophylaxis, and 62 % as secondary prophylaxis, with an average duration of 3 days. Differences between FN and non-FN group which is statistically significance were history of chronic renal failure or anemia (p=0.0038, p<0.0001), prophylactic use of G-CSF (p=0.0192), performance status (p=0.0001), numbers of previous neutropenia (p=0.0008), baseline albumin or hemoglobin level (p=0.0085, p<0.0001). At this cancer center in Taiwan, the duration of G-CSF administration is shorter than the recommended. Differences between the two groups may be the possible risk factors, and need to be further analyzed.